| 137 | Humans |
| 124 | Parkinson Disease |
| 85 | Male |
| 67 | Female |
| 64 | Aged |
| 59 | Middle Aged |
| 49 | Animals |
| 31 | Adult |
| 28 | Aged, 80 and over |
| 20 | Mice |
| 20 | Antiparkinson Agents |
| 19 | Neurons |
| 19 | Brain |
| 18 | Disease Models, Animal |
| 16 | Levodopa |
| 15 | Substantia Nigra |
| 15 | Dopamine |
| 13 | alpha-Synuclein |
| 12 | France |
| 11 | Subthalamic Nucleus |
| 10 | Risk Factors |
| 10 | Mutation |
| 10 | Mice, Inbred C57BL |
| 10 | Deep Brain Stimulation |
| 10 | Corpus Striatum |
| 10 | Case-Control Studies |
| 9 | Rats |
| 9 | Nerve Degeneration |
| 9 | Genetic Predisposition to Disease |
| 8 | Signal Transduction |
| 8 | Severity of Illness Index |
| 8 | Neuropsychological Tests |
| 8 | Mice, Knockout |
| 8 | Double-Blind Method |
| 8 | Basal Ganglia |
| 7 | tau Proteins |
| 7 | Psychomotor Performance |
| 7 | Polymorphism, Single Nucleotide |
| 7 | Pedigree |
| 7 | Parkinsonian Disorders |
| 7 | History, 19th Century |
| 7 | Genotype |
| 7 | Europe |
| 7 | Electric Stimulation Therapy |
| 7 | Dose-Response Relationship, Drug |
| 7 | Dopaminergic Neurons |
| 7 | Dementia |
| 6 | Young Adult |
| 6 | Treatment Outcome |
| 6 | Time Factors |
| 6 | Neural Pathways |
| 6 | Mice, Transgenic |
| 6 | Gene Expression Regulation |
| 6 | Dyskinesia, Drug-Induced |
| 6 | Dopamine Agents |
| 6 | Analysis of Variance |
| 5 | United States |
| 5 | Ubiquitin-Protein Ligases |
| 5 | Parkinson Disease, Secondary |
| 5 | Oxidopamine |
| 5 | Nerve Tissue Proteins |
| 5 | Movement |
| 5 | Immunohistochemistry |
| 5 | History, 20th Century |
| 5 | Depression |
| 5 | Apoptosis |
| 5 | Alzheimer Disease |
| 5 | Age of Onset |
| 5 | Age Factors |
| 5 | Adolescent |
| 5 | Activities of Daily Living |
| 4 | Tyrosine 3-Monooxygenase |
| 4 | Surveys and Questionnaires |
| 4 | Smoking |
| 4 | Reproducibility of Results |
| 4 | Reaction Time |
| 4 | Rats, Sprague-Dawley |
| 4 | RNA, Messenger |
| 4 | Pyridines |
| 4 | Psychiatric Status Rating Scales |
| 4 | Protein Kinases |
| 4 | Piperidines |
| 4 | Phenotype |
| 4 | Neuroprotective Agents |
| 4 | Neurodegenerative Diseases |
| 4 | Mitochondria |
| 4 | MPTP Poisoning |
| 4 | Lewy Bodies |
| 4 | Globus Pallidus |
| 4 | Genetic Linkage |
| 4 | Genetic Association Studies |
| 4 | Frontal Lobe |
| 4 | Disease Progression |
| 4 | Cross-Sectional Studies |
| 4 | Cognition Disorders |
| 4 | Accidental Falls |
| 3 | Survival Rate |
| 3 | Supranuclear Palsy, Progressive |
| 3 | Sex Distribution |
| 3 | Receptors, Dopamine D1 |
| 3 | Randomized Controlled Trials as Topic |
| 3 | Quality of Life |
| 3 | Protein-Serine-Threonine Kinases |
| 3 | Postural Balance |
| 3 | Point Mutation |
| 3 | Phosphorylation |
| 3 | Pedunculopontine Tegmental Nucleus |
| 3 | Oxidative Stress |
| 3 | Nerve Net |
| 3 | Motor Activity |
| 3 | Molecular Sequence Data |
| 3 | Mitochondrial Degradation |
| 3 | Microsatellite Repeats |
| 3 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 3 | Inflammation |
| 3 | Indans |
| 3 | Hypotension, Orthostatic |
| 3 | Huntington Disease |
| 3 | Genome-Wide Association Study |
| 3 | Genetic Variation |
| 3 | Gene Expression |
| 3 | Gait |
| 3 | Follow-Up Studies |
| 3 | Electrophysiology |
| 3 | Electrodes, Implanted |
| 3 | Dyskinesias |
| 3 | Depressive Disorder |
| 3 | DNA Mutational Analysis |
| 3 | Clinical Trials as Topic |
| 3 | Chromosomes, Human, Pair 17 |
| 3 | Cells, Cultured |
| 3 | Cell Death |
| 3 | Blotting, Western |
| 3 | Amino Acid Substitution |
| 3 | Alleles |
| 3 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 2 | Ventral Tegmental Area |
| 2 | Ubiquitin Thiolesterase |
| 2 | Tremor |
| 2 | Tomography, Emission-Computed |
| 2 | Tomography, Emission-Computed, Single-Photon |
| 2 | Thiolester Hydrolases |
| 2 | Tetrahydronaphthalenes |
| 2 | Terminology as Topic |
| 2 | Temporal Lobe |
| 2 | Syndrome |
| 2 | Stroke |
| 2 | Stereotaxic Techniques |
| 2 | Stereoisomerism |
| 2 | Statistics, Nonparametric |
| 2 | Societies, Scientific |
| 2 | Sex Factors |
| 2 | Serotonin |
| 2 | Sequence Homology, Amino Acid |
| 2 | S100 Calcium Binding Protein G |
| 2 | Reference Values |
| 2 | Reference Standards |
| 2 | REM Sleep Behavior Disorder |
| 2 | Pyrenes |
| 2 | Prodrugs |
| 2 | Prodromal Symptoms |
| 2 | Prions |
| 2 | Predictive Value of Tests |
| 2 | Postoperative Care |
| 2 | Polymerase Chain Reaction |
| 2 | Pesticides |
| 2 | Paris |
| 2 | Odds Ratio |
| 2 | Occupational Exposure |
| 2 | Neurology |
| 2 | Neurofibrillary Tangles |
| 2 | Nervous System Diseases |
| 2 | Neostriatum |
| 2 | Neoplasms |
| 2 | Mutation, Missense |
| 2 | Multicenter Studies as Topic |
| 2 | Movement Disorders |
| 2 | Models, Statistical |
| 2 | Models, Molecular |
| 2 | Microglia |
| 2 | Mesencephalon |
| 2 | Membrane Glycoproteins |
| 2 | Medical Records |
| 2 | Markov Chains |
| 2 | Magnetic Resonance Imaging |
| 2 | Macaca fascicularis |
| 2 | Logistic Models |
| 2 | Lod Score |
| 2 | Iron |
| 2 | International Cooperation |
| 2 | Homeodomain Proteins |
| 2 | Heterozygote |
| 2 | Gold |
| 2 | Germany |
| 2 | Genetic Loci |
| 2 | Gene-Environment Interaction |
| 2 | Gene Frequency |
| 2 | Gastrointestinal Tract |
| 2 | Frontotemporal Lobar Degeneration |
| 2 | Family Health |
| 2 | Eye Movements |
| 2 | Exome |
| 2 | European Continental Ancestry Group |
| 2 | Eukaryotic Initiation Factor-4G |
| 2 | Enzyme Inhibitors |
| 2 | Embryo, Mammalian |
| 2 | Electroencephalography |
| 2 | Drug Therapy, Combination |
| 2 | Drug Delivery Systems |
| 2 | Dopamine Agonists |
| 2 | Dominance, Cerebral |
| 2 | Disruptive, Impulse Control, and Conduct Disorders |
| 2 | Diagnosis, Differential |
| 2 | Deglutition Disorders |
| 2 | Databases, Bibliographic |
| 2 | Cues |
| 2 | Cost-Benefit Analysis |
| 2 | Conserved Sequence |
| 2 | Compulsive Behavior |
| 2 | Comorbidity |
| 2 | Cohort Studies |
| 2 | Coffee |
| 2 | Cluster Analysis |
| 2 | Cholinergic Neurons |
| 2 | Child |
| 2 | Cerebral Cortex |
| 2 | Cause of Death |
| 2 | Caspases |
| 2 | Caspase 3 |
| 2 | Carrier Proteins |
| 2 | Calbindins |
| 2 | COS Cells |
| 2 | Brain Mapping |
| 2 | Base Sequence |
| 2 | Autophagy |
| 2 | Apolipoproteins E |
| 2 | Anxiety Disorders |
| 2 | Amyotrophic Lateral Sclerosis |
| 2 | Amino Acid Sequence |
| 2 | Aging |
| 2 | Age Distribution |
| 2 | Affect |
| 2 | Administration, Oral |
| 1 | Wakefulness |
| 1 | Voice |
| 1 | Vocalization, Animal |
| 1 | Vitis |
| 1 | Virulence |
| 1 | Victoria |
| 1 | Vibration |
| 1 | Vesicular Transport Proteins |
| 1 | Ventricular Dysfunction, Left |
| 1 | Urotensins |
| 1 | Urea |
| 1 | Up-Regulation |
| 1 | United Kingdom |
| 1 | Ubiquitins |
| 1 | Turkey |
| 1 | Tumor Suppressor Protein p53 |
| 1 | Triazoles |
| 1 | Transferrin |
| 1 | Transdermal Patch |
| 1 | Transcriptome |
| 1 | Transcription, Genetic |
| 1 | Transcription Factors |
| 1 | Transcranial Magnetic Stimulation |
| 1 | Toxoplasma |
| 1 | Tourette Syndrome |
| 1 | Tomography, X-Ray Computed |
| 1 | Toll-Like Receptor 3 |
| 1 | Tissue Distribution |
| 1 | Thromboembolism |
| 1 | Thalamic Nuclei |
| 1 | Terminal Care |
| 1 | Temperature |
| 1 | Telomere |
| 1 | Telomere Shortening |
| 1 | Telencephalon |
| 1 | TOR Serine-Threonine Kinases |
| 1 | TATA-Box Binding Protein |
| 1 | Synucleins |
| 1 | Synteny |
| 1 | Synaptosomes |
| 1 | Synapses |
| 1 | Swimming |
| 1 | Surface Properties |
| 1 | Substance P |
| 1 | Stilbenes |
| 1 | Stem Cell Niche |
| 1 | Speech |
| 1 | Species Specificity |
| 1 | Solubility |
| 1 | Sodium-Potassium-Exchanging ATPase |
| 1 | Socioeconomic Factors |
| 1 | Sleep, REM |
| 1 | Sleep Disorders, Intrinsic |
| 1 | Sleep Deprivation |
| 1 | Signal Processing, Computer-Assisted |
| 1 | Siblings |
| 1 | Shaw Potassium Channels |
| 1 | Serotonin Syndrome |
| 1 | Serotonin 5-HT2 Receptor Agonists |
| 1 | Serotonin 5-HT1 Receptor Agonists |
| 1 | Sequence Alignment |
| 1 | Sensitivity and Specificity |
| 1 | Secosteroids |
| 1 | Saccharomyces cerevisiae Proteins |
| 1 | Saccades |
| 1 | Ryanodine Receptor Calcium Release Channel |
| 1 | Rivastigmine |
| 1 | Risk |
| 1 | Risk Reduction Behavior |
| 1 | Ribosomal Protein S6 Kinases, 90-kDa |
| 1 | Retrospective Studies |
| 1 | Restriction Mapping |
| 1 | Respiration |
| 1 | Residence Characteristics |
| 1 | Research Design |
| 1 | Regression Analysis |
| 1 | Regional Blood Flow |
| 1 | Referral and Consultation |
| 1 | Recombinant Fusion Proteins |
| 1 | Recognition (Psychology) |
| 1 | Receptors, Transferrin |
| 1 | Receptors, Opioid |
| 1 | Receptors, N-Methyl-D-Aspartate |
| 1 | Receptors, Immunologic |
| 1 | Receptors, Growth Factor |
| 1 | Receptors, Dopamine D2 |
| 1 | Receptor, Metabotropic Glutamate 5 |
| 1 | Receptor, Melanocortin, Type 1 |
| 1 | Receptor Protein-Tyrosine Kinases |
| 1 | Rats, Wistar |
| 1 | Rats, Inbred Strains |
| 1 | ROC Curve |
| 1 | RNA, Double-Stranded |
| 1 | RNA Polymerase II |
| 1 | Quantitative Trait Loci |
| 1 | Quality-Adjusted Life Years |
| 1 | Pyrimidines |
| 1 | PubMed |
| 1 | Psychotic Disorders |
| 1 | Protozoan Proteins |
| 1 | Proton-Translocating ATPases |
| 1 | Proto-Oncogene Proteins |
| 1 | Proto-Oncogene Proteins c-fos |
| 1 | Proteolysis |
| 1 | Proteins |
| 1 | Protein Structure, Secondary |
| 1 | Protein Structure, Quaternary |
| 1 | Protein S |
| 1 | Protein Interaction Maps |
| 1 | Protein Deglycase DJ-1 |
| 1 | Protein Conformation |
| 1 | Protein Biosynthesis |
| 1 | Protein Binding |
| 1 | Protein Aggregation, Pathological |
| 1 | Protein Aggregates |
| 1 | Prospective Studies |
| 1 | Promoter Regions, Genetic |
| 1 | Prognosis |
| 1 | Prion Proteins |
| 1 | Principal Component Analysis |
| 1 | Prevalence |
| 1 | Pressure |
| 1 | Preoperative Care |
| 1 | Practice Guidelines as Topic |
| 1 | Postoperative Period |
| 1 | Polysomnography |
| 1 | Polyglutamic Acid |
| 1 | Poly I-C |
| 1 | Pneumonia, Aspiration |
| 1 | Physical Endurance |
| 1 | Phylogeny |
| 1 | Photic Stimulation |
| 1 | Phosphoproteins |
| 1 | Phenylcarbamates |
| 1 | Phagocytosis |
| 1 | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha |
| 1 | Periaqueductal Gray |
| 1 | Peptide Termination Factors |
| 1 | Peptide Fragments |
| 1 | Penetrance |
| 1 | Patient Selection |
| 1 | Patient Education as Topic |
| 1 | Patient Compliance |
| 1 | Patient Access to Records |
| 1 | Pars Compacta |
| 1 | Parietal Lobe |
| 1 | Parasympathetic Nervous System |
| 1 | Paraquat |
| 1 | Pallidotomy |
| 1 | PTEN Phosphohydrolase |
| 1 | PPAR gamma |
| 1 | Oxygen Consumption |
| 1 | Oximes |
| 1 | Outcome Assessment (Health Care) |
| 1 | Orthopedic Equipment |
| 1 | Organometallic Compounds |
| 1 | Orexins |
| 1 | Oncogene Proteins |
| 1 | Oligopeptides |
| 1 | Oligonucleotide Array Sequence Analysis |
| 1 | Obsessive-Compulsive Disorder |
| 1 | Observer Variation |
| 1 | Obesity |
| 1 | Nursing Homes |
| 1 | Nuclear Receptor Subfamily 4, Group A, Member 2 |
| 1 | Nuclear Family |
| 1 | Nortropanes |
| 1 | Niemann-Pick Diseases |
| 1 | Neurotransmitter Agents |
| 1 | Neurotoxins |
| 1 | Neurotoxicity Syndromes |
| 1 | Neurosurgical Procedures |
| 1 | Neuroprotection |
| 1 | Neurophysiology |
| 1 | Neuroimaging |
| 1 | Neuroglia |
| 1 | Neurogenesis |
| 1 | Neurofeedback |
| 1 | Neural Networks (Computer) |
| 1 | Netherlands |
| 1 | Narcotic Antagonists |
| 1 | Narcolepsy |
| 1 | Naphthalenes |
| 1 | Myoclonic Epilepsies, Progressive |
| 1 | Myocardial Ischemia |
| 1 | Mutagenesis, Site-Directed |
| 1 | Muscle Tonus |
| 1 | Multivariate Analysis |
| 1 | Multiprotein Complexes |
| 1 | Multiple System Atrophy |
| 1 | Multiple Sclerosis |
| 1 | Multimodal Imaging |
| 1 | Motor Skills |
| 1 | Motivation |
| 1 | Motion Perception |
| 1 | Mood Disorders |
| 1 | Monoamine Oxidase |
| 1 | Monoamine Oxidase Inhibitors |
| 1 | Molecular Biology |
| 1 | Models, Neurological |
| 1 | Models, Chemical |
| 1 | Mitochondrial Proteins |
| 1 | Mitochondrial Dynamics |
| 1 | Mitochondrial Diseases |
| 1 | Microscopy, Electron |
| 1 | Microscopy, Electron, Transmission |
| 1 | Microscopy, Electron, Scanning Transmission |
| 1 | Microbiota |
| 1 | Metabolic Syndrome X |
| 1 | Metabolic Networks and Pathways |
| 1 | Meta-Analysis as Topic |
| 1 | Mercury Compounds |
| 1 | Mental Disorders |
| 1 | Memory |
| 1 | Memory Disorders |
| 1 | Membrane Potential, Mitochondrial |
| 1 | Melanoma |
| 1 | Medical Illustration |
| 1 | Mass Spectrometry |
| 1 | Macrolides |
| 1 | Macaca |
| 1 | Lysosomes |
| 1 | Loss of Heterozygosity |
| 1 | Longitudinal Studies |
| 1 | Locomotion |
| 1 | Linkage Disequilibrium |
| 1 | Ligases |
| 1 | Ligands |
| 1 | Laughter |
| 1 | Lab-On-A-Chip Devices |
| 1 | Japan |
| 1 | Italy |
| 1 | Iron-Binding Proteins |
| 1 | Ions |
| 1 | Intracellular Signaling Peptides and Proteins |
| 1 | Intermediate Filaments |
| 1 | Interferon-gamma |
| 1 | Intercellular Signaling Peptides and Proteins |
| 1 | Insulin Resistance |
| 1 | Injections |
| 1 | Infection |
| 1 | Infant |
| 1 | Indoles |
| 1 | Incidence |
| 1 | Impulsive Behavior |
| 1 | Immunoprecipitation |
| 1 | Immunoblotting |
| 1 | Immune System |
| 1 | Immune Sera |
| 1 | Imidazoles |
| 1 | Imaging, Three-Dimensional |
| 1 | Image Processing, Computer-Assisted |
| 1 | Hypokinesia |
| 1 | Huntingtin Protein |
| 1 | Hospitals |
| 1 | Hospitals, Urban |
| 1 | Hospital Bed Capacity |
